Keyphrases
Curcumin
100%
Non-small Cell Lung Cancer (NSCLC)
100%
Subcutaneous Delivery
100%
Therapeutic Efficacy
22%
Tumor
22%
Liposomal Curcumin
22%
Nanoformulation
22%
Route of Administration
11%
Immunohistochemistry
11%
Low Immunogenicity
11%
Tumor Growth
11%
Annexin A2 (ANXA2)
11%
Antiangiogenic Activity
11%
Quality of Life
11%
Cancer Patients
11%
Reduced Expression
11%
Poor Prognosis
11%
Histology
11%
Cancer Growth
11%
Murine Xenografts
11%
Systemic Bioavailability
11%
Low Water Solubility
11%
A2 Protein
11%
Xenograft Mice
11%
Drug Efficacy
11%
Subcutaneous Injection
11%
Natural Anticancer Agents
11%
Formulation Method
11%
Tumor Section
11%
P65 Subunit
11%
Survival Rate
11%
Patient Compliance
11%
Subcutaneous Route
11%
Proliferation Marker Ki-67
11%
Novel Hybrids
11%
Human Non-small Cell Lung Cancer
11%
Cancer Xenograft Model
11%
Advanced Therapies
11%
Patient Quality
11%
Lung Cancer Treatment
11%
A549
11%
Xenograft Model
11%
Anticancer Effect
11%
Curcumin Nanoemulsion
11%
Biochemistry, Genetics and Molecular Biology
Anticancer
100%
Annexin A2
50%
Tumor Progression
50%
Antiangiogenic Activity
50%
Nude Mouse
50%
In Vivo Study
50%
Survival Rate
50%
Drug Efficacy
50%
Immunogenicity
50%
Patient Compliance
50%
Pharmacology, Toxicology and Pharmaceutical Science
Curcumin
100%
Non Small Cell Lung Cancer
100%
Neoplasm
33%
Combination Therapy
16%
Cancer Growth
8%
Malignant Neoplasm
8%
Side Effect
8%
Anticarcinogen
8%
Immunogenicity
8%
Tumor Growth
8%
Lipocortin 2
8%
Antiangiogenic
8%
Bioavailability
8%
Route of Administration
8%
Nude Mouse
8%
Subcutaneous Injection
8%
Survival Rate
8%
Subcutaneous Route
8%